【私募调研记录】源乐晟资产调研博瑞医药

Group 1 - Source Le Sheng Asset Management conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to expedite the commercialization of the BGM0504 product in China [1] - China Resources Sanjiu is confident in the BGM0504 product and plans to conduct more clinical trials to demonstrate its advantages, indicating a strong partnership [1] - The BGM0504 product is expected to have global competitiveness and plans for international expansion without affecting global rights [1] Group 2 - BGM1812 is characterized by fat reduction without muscle loss and has mild side effects, with ongoing IND applications in China and the US [1] - The collaboration with Hanyu Pharmaceutical is aimed at preparing for future commercialization needs and regulatory market clinical and industrialization [1]